吉非替尼联合吉西他滨和顺铂治疗非小细胞肺癌的临床研究

Clinical Study of Treatment of non-small Cell Lung Cancer with Gefi tinib in Conjunction with Gemcitabine and Cisplatin

目的探讨吉非替尼联合吉西他滨和顺铂治疗非小细胞肺癌(NSCLC)的临床疗效,提高患者的生存质量。方法选择符合标准的NSCLC患者80例,随机分为观察组和对照组各40例,两组患者均给予吉西他滨和顺铂,观察组加用吉非替尼,比较二者临床疗效及生活质量。结果观察组患者临床疗效明显优于对照组,差异有统计学意义(P<0.05)。两组患者毒性反应类型、发生率及分级相似,差异无统计学意义(P>0.05)。两组患者治疗前肺癌症状量表(LCSS)评分相似,差异无统计学意义(P>0.05);疗程结束时,观察组患者LCSS评分较治疗前下降,差异有统计学意义(P<0.05),而对照组患者改善不明显,差异无统计学意义(P>0.05)。结论吉非替尼联合吉西他滨和顺铂治疗NSCLC临床疗效显著,不增加毒副反应,有效改善患者生活质量,值得临床推广应用。

Objective To investigate the clinical effi cacy of the treatment of non-small cell lung cancer（NSCLC） with gefi tinib in conjunction with gemcitabine and cisplatin and to improve patients＇ quality of life. Methods Eighty selected NSCLC patients who met the inclusion criteria were randomized into observation group（n=40） and control group（n=40）. Gemcitabine and cisplatin were given in both groups, while additional gefitinib was given in the observation group. Clinical effi cacy and quality of life were compared between both groups. Results Patients in the observation group had remarkably better clinical effi cacy than those in the control group, with a statistically signifi cant difference（P〈0.05）. Patients in both groups had similar type, incidence and classification of the toxic reaction, and differences were not statistically significant（P〈0.05）. Both groups had similar pretreatment LCSS scores, and the difference was not statistically signifi cant（P〈0.05）; at the end of therapy, LCSS scores in the observation group decreased compared with pretreatment, with a statistically significant difference（P〈0.05）, but those in the control group were not markedly improved and the difference was not statistically signifi cant（P〈0.05）. Conclusion Treatment of NSCLC with gefi tinib in conjunction with gemcitabine and cisplatin is worthy of clinical popularization and application due to its remarkable clinical efficacy, less toxic reaction and effective improvement of patients＇ quality of life.